- Novor V2.0 software with novel ML algorithm trained on
HLA peptides yields immunopeptidome from de novo peptide sequencing
with further improved IDs
- TwinScape™ digital-twin technology with iRT™ standards
supports highest timsTOF performance with intelligent feedback –
well beyond ‘just up-time’
- New glyco-PASEF® method for ultra-high sensitivity 4D
glycopeptide analysis
- Spectronaut® 18 software now available for Bruker
ProteoScape™ users
- Biognosys launches high-throughput ENRICHMENT plasma
proteomics service for large-scale quantification of ~4.5k
proteins with ~55k peptides at 1% FDR specificity
- PreOmics® sample prep tools for proteomics now with
>50 BeatBox® placements for fast cell lysis and
affordable, high-performance FFPE/FF tissue homogenization
At the 20th US Human Proteome Organization Congress 2024, Bruker
Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics,
glycoproteomics and other CCS-enabled 4D-proteomics workflows. The
rapid advances in deep, at-scale proteomics, glycomics and
peptidomics research solutions complement other performance-leading
life-science tools for the post-genomic era by Bruker. Together
they enable post-genomic molecular and cell biology research, with
key insights into disease biology and biomarkers for next-gen
molecular diagnostics and drug discovery.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240311088724/en/
Bruker's Immunopeptidomics Workflow
(Graphic: Business Wire)
The advances featured at US HUPO include improved
machine-learning de novo sequencing (Novor V2.0), a novel
high-performance monitoring digital-twin software (TwinScape), the
new glyco-PASEF method for high-sensitivity glycopeptide analysis,
and access to Spectronaut 18 for users of Bruker ProteoScape, a
GPU-powered software for real-time 4D proteomics, now with access
to library-free searches by Biognosys directDIA®.
A. Advancing Cancer Immunotherapy Research
Bruker enhances its timsTOF HT and timsTOF Ultra systems with
the new software Novor v2.0 for de novo immunopeptidomic profiling.
Novor v2.0, developed in collaboration with Rapid Novor Inc., was
trained on >1,400,000 spectra mapping to >150,000 HLA
peptides for research on small amounts of patient material derived
from fine needle biopsies.
Dr. Juliane Walz, Professor of Peptide-based Immunotherapy and
Medical Director for Translational Immunology at
Universitätsklinikum Tübingen in Germany commented: “Our research
focuses on the field of immunology and the development of novel
peptide-based immunotherapy concepts for tumor and infectious
diseases. Bruker’s trapped ion mobility separation combination with
time-of-flight mass spectrometry enables immunopeptidomics with
high speed and sensitive detection of HLA-presented peptides.
Applying this technology, we have expanded the benign reference
immunopeptidome databases with >150,000 HLA peptides. This
allows us to confidently define tumor-associated antigens to
fast-track immunotherapy development.”
B. Peak timsTOF Performance using TwinScape
TwinScape is a new digital-twin performance monitoring and
quality control engine, leveraging iRT peptide standards to support
sustained peak performance in sample prep and LC-MS. For
synergistic multi-omics studies in the post-genomic era, a
combination of depth of coverage, robustness, and scalable
quantitation is required. TwinScape enables larger controlled
studies and valid cross-lab comparability.
Dr. Anne-Claude Gingras, VP of Research at Sinai Health,
Director at Lunenfeld-Tanenbaum Research Institute, and Professor
in Molecular Genetics in Toronto, Canada said: “We support a
variety of projects in our proteomics facility. It is critical that
our instruments are at peak performance and that we always have a
pulse on them. The combination of Bruker ProteoScape, TwinScape and
the Biognosys iRT kit have become integral for monitoring our
instruments to ensure everything is operating up to highest
standards. TwinScape is great for an over-time view of QC and
system performance. It has been especially useful in pinpointing if
there ever is a sample, LC or MS problem.”
C. New glyco-PASEF for Ultra-High Sensitivity 4D-Glycopeptide
Analysis
Bruker presents the novel timsTOF glyco-PASEF method with
polygon filtering developed with the Heck Group at Utrecht
University, the GlycoScape software developed collaboratively with
the Van Gool Group at Radboud University, and MSFragger-Glyco
software developed by the Nesvizhskii Group at the University of
Michigan.
Dr. Albert Heck, Professor of Chemistry and Pharmaceutical
Sciences at Utrecht University and Scientific Director of the
Netherlands Proteomics Center, noted: “I am pleased with our
pioneering work in leveraging the unique strengths of the timsTOF
platform for glycoproteomics, now translated to the glyco-PASEF
method for research in glycobiology.”
Bruker is now offering GlycoScape™ real-time glycoproteomic
software, developed with Alain van Gool’s team at Radboud
University, for early access beta-testing.
Bruker also announces that the MSFragger-Glyco software now
supports timsTOF data. Dr. Alexey Nesvizhskii, Professor of
Computational Medicine, Bioinformatics and Pathology at University
of Michigan, and creator of MSFragger, stated: “My team is
gratified by the popularity of MSFragger for ultrafast searches,
including the identification of post-translationally modified
peptides. Our software suite supports the analysis of PASEF data,
and we are delighted that Bruker now offers it with timsTOF
instruments. This recognition acknowledges the broad applicability
of our tools to timsTOF-generated proteomics data.”
D. Software Advances for dia-PASEF®
The newest release of Bruker ProteoScape makes a Spectronaut 18
module available for dia-PASEF analysis, enabling real-time results
using GPU computing, including directDIA for library-free searches.
Bruker ProteoScape now also upgrades TIMS DIA-NN software to
version 3.0 with improved quantitation accuracy.
About Bruker Corporation – the Emerging Leader of the
Post-Genomic Era
Bruker (Nasdaq: BRKR) is enabling scientists to make
breakthrough post-genomic discoveries and develop new applications
that improve the quality of human life. Bruker’s high performance
scientific instruments and high value analytical and diagnostic
solutions enable scientists to explore life and materials at
molecular, cellular, and microscopic levels. In close cooperation
with our customers, Bruker is enabling innovation, improved
productivity, and customer success in post-genomic life science
molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311088724/en/
Media Contact Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Contact Justin Ward Sr. Director
Investor Relations & Corp Development T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
過去 株価チャート
から 4 2024 まで 5 2024
Bruker (NASDAQ:BRKR)
過去 株価チャート
から 5 2023 まで 5 2024